- Country: USA
- Summary: Early-Stage Development of Data Science Technologies for Infectious and Immune-Mediated Diseases (U01 Clinical Trial not Allowed)
- UST Ref No: 51354293
- Deadline: 06 Jul 2023
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: USD 1350000
- Notice Type: Tender
- Document Ref. No.: RFA-AI-21-020
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Tender are invited for Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed)
CFDA Number : 93.855 -- Allergy and Infectious Diseases Research
Cost Sharing or Matching Requirement : No
Estimated Total Program Funding : $1,350,000
Closing Date for Applications: Jul 06, 2023
Posted Date : Mar 17, 2021
Description: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID data science program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. This contrasts with exploratory (R21) and e... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINEarly-Stage Development of Data Science Technologies for Infectious and Immune-Mediated Diseases (U01 Clinical Trial not Allowed) - USA Tender
The NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Early-Stage Development of Data Science Technologies for Infectious and Immune-Mediated Diseases (U01 Clinical Trial not Allowed). This tender is published on USARFP under UST Ref No: 51354293 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-07-06.
The estimated tender value is USD 1350000, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
